Add-on of anti-PD-1 therapy to BRAF/MEK inhibition in patients with poor-prognosis stage IV BRAFV600-mutant melanoma, a retrospective case series
EJC Skin Cancer · 2026 · 4 · 100795
DOI: 10.1016/j.ejcskn.2026.100795 ↗Kurz gefasst
Fachartikel in der Zeitschrift EJC Skin Cancer, 2026. Verfasst von C. Bertels und 3 weiteren Autor:innen. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Kein Abstract verfügbar.
Zitieren
APA
Bertels, C., Talhaoui, D., Dirven, I., & Neyns, B. (2026). Add-on of anti-PD-1 therapy to BRAF/MEK inhibition in patients with poor-prognosis stage IV BRAFV600-mutant melanoma, a retrospective case series. EJC Skin Cancer, 4, 100795. https://doi.org/10.1016/j.ejcskn.2026.100795
Vancouver
Bertels C, Talhaoui D, Dirven I, Neyns B. Add-on of anti-PD-1 therapy to BRAF/MEK inhibition in patients with poor-prognosis stage IV BRAFV600-mutant melanoma, a retrospective case series. EJC Skin Cancer. 2026;4:100795. doi:10.1016/j.ejcskn.2026.100795
BibTeX
@article{Bertels2026,
author = {Bertels, C. and Talhaoui, D. and Dirven, I. and Neyns, B.},
title = {Add-on of anti-PD-1 therapy to BRAF/MEK inhibition in patients with poor-prognosis stage IV BRAFV600-mutant melanoma, a retrospective case series},
journal = {EJC Skin Cancer},
year = {2026},
volume = {4},
pages = {100795},
doi = {10.1016/j.ejcskn.2026.100795}
}
EUVIMED